2. Academic Validation
  3. Evidence on the identity of the CXCR2 antagonist AZD-5069

Evidence on the identity of the CXCR2 antagonist AZD-5069

  • Expert Opin Ther Pat. 2013 Jan;23(1):113-7. doi: 10.1517/13543776.2012.725724.
Peter Norman 1
Affiliations

Affiliation

  • 1 Norman Consulting, Burnham, Bucks, UK. peter.norman2@btinternet.com
PMID: 22992174 DOI: 10.1517/13543776.2012.725724
Abstract

Crystalline forms A and D of N-[2-[[(2,3-difluoropheny)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide are claimed. The compound is a previously disclosed CXCR2 Chemokine Receptor antagonist and is claimed to be useful in the treatment of inflammatory diseases such as chronic obstructive pulmonary disease (COPD).

Figures
Products